| Preoperative psychosocial risk factors for poor outcomes at 1 and 5 years after total knee replacement: A cohort study of 266 patients V Wylde, L Trela-Larsen, MR Whitehouse, AW Blom Acta orthopaedica 88 (5), 530-536, 2017 | 70 | 2017 |
| Body mass index, body dissatisfaction and adolescent smoking initiation LJ Howe, L Trela-Larsen, M Taylor, J Heron, MR Munafò, AE Taylor Drug and alcohol dependence 178, 143-149, 2017 | 44 | 2017 |
| Understanding the challenges and uncertainties of seroprevalence studies for SARS-CoV-2 D McConnell, C Hickey, N Bargary, L Trela-Larsen, C Walsh, M Barry, ... International Journal of Environmental Research and Public Health 18 (9), 4640, 2021 | 31 | 2021 |
| Estimating an individual’s probability of revision surgery after knee replacement: a comparison of modeling approaches using a national data set P Aram, L Trela-Larsen, A Sayers, AF Hills, AW Blom, EV McCloskey, ... American journal of epidemiology 187 (10), 2252-2262, 2018 | 22 | 2018 |
| Chlamydia screening, retesting and repeat diagnoses in Cornwall, UK 2003–2009 KME Turner, PJ Horner, L Trela-Larsen, M Sharp, M May Sexually transmitted infections 89 (1), 70-75, 2013 | 17 | 2013 |
| The association between cement type and the subsequent risk of revision surgery in primary total hip replacement: 199, 205 hips from the National Joint Registry for England … L Trela-Larsen, A Sayers, AW Blom, JCJ Webb, MR Whitehouse Acta orthopaedica 89 (1), 40-46, 2018 | 16 | 2018 |
| Coronavirus disease 2019: considerations for health technology assessment from the National Centre for Pharmacoeconomics Review Group J Leahy, C Hickey, D McConnell, O Cassidy, L Trela-Larsen, M Barry, ... Value in Health 23 (11), 1423-1426, 2020 | 14 | 2020 |
| HAPRAP: a haplotype-based iterative method for statistical fine mapping using GWAS summary statistics J Zheng, S Rodriguez, C Laurin, D Baird, L Trela-Larsen, ... Bioinformatics 33 (1), 79-86, 2017 | 10 | 2017 |
| Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: Cost-effectiveness and value of information analysis N Carey, J Leahy, L Trela-Larsen, L McCullagh, M Barry International Journal of Technology Assessment in Health Care 38 (1), 2022 | 4 | 2022 |
| Personalized estimation of one-year mortality risk after elective hip or knee arthroplasty for osteoarthritis: JointCalc model development and validation using the National … L Trela-Larsen, G Kroken, C Bartz-Johannessen, A Sayers, P Aram, ... Bone & Joint Research 9 (11), 808-820, 2020 | 4 | 2020 |
| A comparison of relative-efficacy estimate (s) derived from both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons O Cassidy, M Harte, L Trela-Larsen, C Walsh, A White, L McCullagh, ... Value in Health, 2023 | 1 | 2023 |
| Revision and 90-day mortality following hip arthroplasty in patients with inflammatory arthritis and ankylosing spondylitis enrolled in the National Joint Registry for England … LL Miller, D Prieto-Alhambra, L Trela-Larsen, JM Wilkinson, EM Clark, ... Hip International 32 (3), 371-378, 2022 | 1 | 2022 |
| Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective C Kennedy, L McCullagh, R Adams, L Trela-Larsen, L Tilson, M Barry Value in Health 24 (10), 1402-1406, 2021 | 1 | 2021 |
| Estimating patient-specific mortality after joint replacement: algorithm development and validation using national audit datasets JM Wilkinson, L Trela-Larsen, C Bartz-Johannessen, A Sayers, P Aram, ... Osteoarthritis and Cartilage 27, S229, 2019 | 1 | 2019 |
| An evaluation of survival modelling approaches for personalised risk prediction after hip replacement for osteoarthritis P Aram, L Trela-Larsen, A Sayers, AF Hills, AW Blom, EV McCloskey, ... Osteoarthritis and Cartilage 26, S281, 2018 | 1 | 2018 |
| P5-S7. 07 Chlamydia screening in Cornwall: How often do young people get retested? K Turner, L Trela-Larsen, P Gates, M May, P Horner Sexually Transmitted Infections 87 (Suppl 1), A344-A345, 2011 | 1 | 2011 |
| Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting N Carey, J Leahy, L Trela-Larsen, L Mc Cullagh, M Barry Journal of Market Access & Health Policy 11 (1), 2166375, 2023 | | 2023 |
| HTA82 Surrogate Measures and the Health Technology Assessment of Cancer Drugs in Ireland: A Retrospective Analysis of EMA Cancer Drug Indication Approvals Between 2017 and 2022 … A Assi, T Karbanova, L Alghawas, YXD Lim, L Trela-Larsen, C Usher, ... Value in Health 26 (12), S334, 2023 | | 2023 |
| HTA90 Quality of Clinical Evidence Submitted to a National HTA Agency in Ireland: 10 Years of Drugs for Oncology H Eames, J Leahy, L Trela-Larsen, L Mccullagh Value in Health 26 (12), S336, 2023 | | 2023 |
| EE569 Axicabtagene Ciloleucel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Irish Healthcare Setting: Cost-Utility and Value of Information Analysis N Carey, J Leahy, L Trela-Larsen, L Mccullagh, M Barry Value in Health 25 (12), S167, 2022 | | 2022 |
